Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cancer And Rare Diseases Top EU Drug Approvals In 2015

This article was originally published in Scrip

Executive Summary

  • 46 new active substances approved
  • First stem cell therapy
  • First drug for mitochondrial dysfunction
  • 12 new anticancers
  • 16 drugs for rare diseases
  • Five accelerated approvals
  • Four conditional approvals
  • Three exceptional circumstances approvals
  • Second-highest number of CHMP recommendations
  • You may also be interested in...

    

    AZ Will Sideline ‘Lucky Mistake’ Data To Secure COVID-19 Vaccine Approval

    A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.

    Clinuvel’s Phototoxicity Drug Scenesse Approved In Third Market

    Australian patients with phototoxicity due to the rare condition EPP will now have their first treatment option – provided the drug's developer, Clinuvel, secures reimbursement under the Pharmaceutical Benefits Scheme.

    EU Plans IP Law Shake-Up

    European Commission proposals for strengthening intellectual property protections in the EU, particularly the supplementary protection certificate (SPC) system, have been broadly welcomed by the European pharmaceutical industry federation EFPIA. But the medical NGO, MSF, says the SPC proposals run counter to the commission’s own efforts to improve access to medicines.

    Topics

    UsernamePublicRestriction

    Register

    LL1134478

    Ask The Analyst

    Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

    Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

    All fields are required.

    Please make sure all fields are completed.

    Please make sure you have filled out all fields

    Please make sure you have filled out all fields

    Please enter a valid e-mail address

    Please enter a valid Phone Number

    Ask your question to our analysts

    Cancel